<DOC>
	<DOCNO>NCT00770354</DOCNO>
	<brief_summary>The aim study compare overall tumour response rate per RECIST postmenopausal woman metastatic locally advanced breast cancer receive AS1402 combination letrozole compare letrozole alone</brief_summary>
	<brief_title>Phase II Study AS1402 Combined With Letrozole Treat Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Histologically cytologically confirm locally advance metastatic breast cancer amenable curative therapy Measurable disease accord RECIST criterion Documented estrogen receptorpositive and/or progesterone receptorpositive tumour Postmenopausal woman Prior chemotherapy and/or endocrine therapy advance breast disease Relapse within 12 month treatment discontinuation aromatase inhibitor adjuvant set Unknown hormonal receptor status Known HER2/neupositivity</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Breast cancer</keyword>
</DOC>